Natalia G Rocha1, Danielle L Templeton2, Jared J Greiner2, Brian L Stauffer3, Christopher A DeSouza4. 1. Integrative Vascular Biology Laboratory, Department of Integrative Physiology, University of Colorado, Boulder, CO 80309; Department of Physiology and Pharmacology, Fluminense Federal University, Niteroi, RJ, 24210-130. 2. Integrative Vascular Biology Laboratory, Department of Integrative Physiology, University of Colorado, Boulder, CO 80309. 3. Integrative Vascular Biology Laboratory, Department of Integrative Physiology, University of Colorado, Boulder, CO 80309; Department of Medicine, University of Colorado Denver and the Health Sciences Center, Aurora, CO 80045; Denver Health Medical Center, Denver, CO 80204. 4. Integrative Vascular Biology Laboratory, Department of Integrative Physiology, University of Colorado, Boulder, CO 80309; Department of Medicine, University of Colorado Denver and the Health Sciences Center, Aurora, CO 80045. Electronic address: desouzac@colorado.edu.
Abstract
OBJECTIVE: To determine whether endothelin (ET)-1 vasoconstrictor tone is greater in overweight and obese adults with the metabolic syndrome (MetS). MATERIALS/ METHODS: Forty overweight/obese middle-aged and older adults (age: 43-71 years; BMI: 25.1-36.9 kg/m²) were studied: 20 without MetS (13 M/7 F) and 20 with MetS (13 M/7 F). MetS was established according to NCEP ATP III guidelines. Forearm blood flow (FBF; plethysmography) responses to intra-arterial infusion of selective ET(A) receptor blockade (BQ-123; 100 nmol/min; for 60 min) and non-selective ET(A/B) receptor blockade (BQ-123 + BQ-788 [50 nmol/min for 60 min]) were determined. RESULTS: In response to the selective ET(A) antagonism, there was a significant increase in forearm blood flow from baseline in both groups. However, the increase in forearm blood flow was significantly higher (P=0.03; ~45%) in the overweight/obese group with MetS than the group without MetS. In contrast, there were no significant group differences in FBF responses to non-selective ET(A/B) receptor blockade. Peak vasodilator responses to nonselective ET(A/B) blockade were ~50% higher than baseline blood flow in the overweight/obese groups without and with MetS. CONCLUSION: MetS is associated with higher ET-1 vasoconstrictor tone in overweight/obese adults. The enhanced ET-1 vasoconstrictor activity with MetS is mediated by the ET(A) receptor subtype.
OBJECTIVE: To determine whether endothelin (ET)-1 vasoconstrictor tone is greater in overweight and obese adults with the metabolic syndrome (MetS). MATERIALS/ METHODS: Forty overweight/obese middle-aged and older adults (age: 43-71 years; BMI: 25.1-36.9 kg/m²) were studied: 20 without MetS (13 M/7 F) and 20 with MetS (13 M/7 F). MetS was established according to NCEP ATP III guidelines. Forearm blood flow (FBF; plethysmography) responses to intra-arterial infusion of selective ET(A) receptor blockade (BQ-123; 100 nmol/min; for 60 min) and non-selective ET(A/B) receptor blockade (BQ-123 + BQ-788 [50 nmol/min for 60 min]) were determined. RESULTS: In response to the selective ET(A) antagonism, there was a significant increase in forearm blood flow from baseline in both groups. However, the increase in forearm blood flow was significantly higher (P=0.03; ~45%) in the overweight/obese group with MetS than the group without MetS. In contrast, there were no significant group differences in FBF responses to non-selective ET(A/B) receptor blockade. Peak vasodilator responses to nonselective ET(A/B) blockade were ~50% higher than baseline blood flow in the overweight/obese groups without and with MetS. CONCLUSION: MetS is associated with higher ET-1 vasoconstrictor tone in overweight/obese adults. The enhanced ET-1 vasoconstrictor activity with MetS is mediated by the ET(A) receptor subtype.
Authors: Scott M Grundy; H Bryan Brewer; James I Cleeman; Sidney C Smith; Claude Lenfant Journal: Arterioscler Thromb Vasc Biol Date: 2004-02 Impact factor: 8.311
Authors: Zachary I Grunewald; Thomas J Jurrissen; Makenzie L Woodford; Francisco I Ramirez-Perez; Lauren K Park; Ryan Pettit-Mee; Thaysa Ghiarone; Scott M Brown; Mariana Morales-Quinones; James R Ball; Kevin F Staveley-O'Carroll; Annayya R Aroor; Paul J Fadel; Pierre Paradis; Ernesto L Schiffrin; Shawn B Bender; Luis A Martinez-Lemus; Jaume Padilla Journal: Hypertension Date: 2019-10-21 Impact factor: 10.190
Authors: Paul J Meakin; Bethany M Coull; Zofia Tuharska; Christopher McCaffery; Ioannis Akoumianakis; Charalambos Antoniades; Jane Brown; Kathryn J Griffin; Fiona Platt; Claire H Ozber; Nadira Y Yuldasheva; Natallia Makava; Anna Skromna; Alan Prescott; Alison D McNeilly; Moneeza Siddiqui; Colin Na Palmer; Faisel Khan; Michael Lj Ashford Journal: J Clin Invest Date: 2020-08-03 Impact factor: 14.808
Authors: Mario de la Fuente Muñoz; María de la Fuente Fernández; Marta Román-Carmena; Maria Del Carmen Iglesias de la Cruz; Sara Amor; Patricia Martorell; María Enrique-López; Angel Luis García-Villalón; Antonio Manuel Inarejos-García; Miriam Granado Journal: Antioxidants (Basel) Date: 2022-08-15